Safety and effectiveness of isavuconazole in real-life non-neutropenic patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: Canada NLM ID: 9610933 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3511 (Electronic) Linking ISSN: 12019712 NLM ISO Abbreviation: Int J Infect Dis Subsets: MEDLINE
    • Publication Information:
      Publication: Hamilton, ON : Elsevier
      Original Publication: Hamilton, ON : Decker, c1996-
    • Subject Terms:
      Nitriles*/therapeutic use ; Nitriles*/adverse effects ; Pyridines*/therapeutic use ; Pyridines*/adverse effects ; Antifungal Agents*/therapeutic use ; Antifungal Agents*/adverse effects ; Triazoles*/therapeutic use ; Triazoles*/adverse effects ; Invasive Fungal Infections*/drug therapy; Humans ; Retrospective Studies ; Female ; Male ; Middle Aged ; Aged ; Adult ; Treatment Outcome ; Aged, 80 and over ; Aspergillosis/drug therapy ; Young Adult
    • Abstract:
      Objectives: Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life.
      Methods: A retrospective, observational multicentric study of non-neutropenic patients who received isavuconazole as an IFI treatment at 12 different university hospitals (January 2018-2022). All patients met criteria for proven, probable or possible IFI according to EORTC-MSG.
      Results: A total of 238 IFIs were treated with isavuconazole during the study period. Combination therapy was administered in 27.7% of cases. The primary IFI was aspergillosis (217, 91.2%). Other IFIs treated with isavuconazole were candidemia (n = 10), mucormycosis (n = 8), histoplasmosis (n = 2), cryptococcosis (n = 2), and others (n = 4). Median time of isavuconazole treatment was 29 days. Only 5.9% (n = 14) of cases developed toxicity, mainly hepatic-related (10 patients, 4.2%). Nine patients (3.8%) had treatment withdrawn. Successful clinical response at 12 weeks was documented in 50.5% of patients.
      Conclusion: Isavuconazole is an adequate treatment for non-neutropenic patients with IFIs. Toxicity rates were low and its effectiveness was comparable to other antifungal therapies previously reported.
      (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
    • Comments:
      Erratum in: Int J Infect Dis. 2024 Sep;146:107188. doi: 10.1016/j.ijid.2024.107188. (PMID: 39067149)
    • Contributed Indexing:
      Keywords: Effectiveness; Invasive fungal infection; Isavuconazole; Non-neutropenic; Safety
    • Accession Number:
      60UTO373KE (isavuconazole)
      0 (Nitriles)
      0 (Pyridines)
      0 (Antifungal Agents)
      0 (Triazoles)
    • Publication Date:
      Date Created: 20240425 Date Completed: 20240530 Latest Revision: 20240814
    • Publication Date:
      20240815
    • Accession Number:
      10.1016/j.ijid.2024.107070
    • Accession Number:
      38663477